Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

The costs of treating glaucoma with combinations of topical drugs in Spain.

Neymark N, Buchholz P, Honrubia F, Kobelt G.

Eur J Ophthalmol. 2008 Jan-Feb;18(1):52-9.

PMID:
18203085
2.

Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer.

Neymark N, Lianes P, Smit EF, van Meerbeeck JP.

Pharmacoeconomics. 2005;23(11):1155-66.

PMID:
16277550
4.

Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.

Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F, Smit H, Gaafar R, Biesma B, Manegold C, Neymark N, Giaccone G; European Organization for Research and Treatment of Cancer Lung Cancer Group.

J Clin Oncol. 2003 Nov 1;21(21):3909-17.

PMID:
14581415
5.

Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group.

Oosterhof GO, Roberts JT, de Reijke TM, Engelholm SA, Horenblas S, von der Maase H, Neymark N, Debois M, Collette L.

Eur Urol. 2003 Nov;44(5):519-26.

PMID:
14572748
6.

Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium.

Neymark N, Gorlia T, Adriaenssen I, Baron B, Piccart M.

Pharmacoeconomics. 2002;20(7):485-97.

PMID:
12093304
8.

Health Economics Unit achievements.

Crott R, Neymark N.

Eur J Cancer. 2002 Mar;38 Suppl 4:S147-50.

PMID:
11858982
9.

Assessment of the economic value of epoetin use in anemic cancer patients.

Neymark N.

Expert Rev Pharmacoecon Outcomes Res. 2001 Dec;1(2):167-75. doi: 10.1586/14737167.1.2.167.

PMID:
19807404
10.
11.

Assessing the quality of economic evaluations of health care interventions.

Neymark N.

Ann Oncol. 2000 Dec;11(12):1513-5. No abstract available.

PMID:
11205456
13.

The costs of managing patients with advanced colorectal cancer in 10 different European centres.

Neymark N, Adriaenssen I.

Eur J Cancer. 1999 Dec;35(13):1789-95.

PMID:
10673993
14.

How should treatment costs impact on physician's decisions?

Neymark N.

Acta Otorhinolaryngol Belg. 1999;53(3):289-92.

PMID:
10635410
15.

Cost-minimization analysis of treatment options for T1N0 glottic squamous cell carcinoma: comparison between external radiotherapy, laser microsurgery and partial laryngectomy.

Grégoire V, Hamoir M, Rosier JF, Counoy H, Eeckhoudt L, Neymark N, Scalliet P.

Radiother Oncol. 1999 Oct;53(1):1-13.

PMID:
10624847
16.

Techniques for health economics analysis in oncology: Part 2.

Neymark N.

Crit Rev Oncol Hematol. 1999 Mar;30(1):13-24. Review. No abstract available.

PMID:
10439050
17.

Techniques for health economics analysis in oncology: Part 1.

Neymark N.

Crit Rev Oncol Hematol. 1999 Mar;30(1):1-11. Review. No abstract available.

PMID:
10439049
18.
19.

Critical reviews of economic analyses in order to make health care decisions for cancer.

Neymark N.

Ann Oncol. 1998 Nov;9(11):1167-72. No abstract available.

PMID:
9862045
20.

Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials: report of a workshop.

Neymark N, Kiebert W, Torfs K, Davies L, Fayers P, Hillner B, Gelber R, Guyatt G, Kind P, Machin D, Nord E, Osoba D, Revicki D, Schulman K, Simpson K.

Eur J Cancer. 1998 Aug;34(9):1317-33.

PMID:
9849412
21.

Moving beyond acquisition cost reductionism.

Neymark N.

Support Care Cancer. 1998 Nov;6(6):488-9. No abstract available.

PMID:
9833294
22.

First European Conference on the Economics of Cancer.

Neymark N.

Eur J Cancer. 1998 May;34(6):809. No abstract available.

PMID:
9797689
23.

Assessing the economic value of anticancer therapies.

Neymark N.

Recent Results Cancer Res. 1998;148:1-285. No abstract available.

PMID:
9670279
24.

Economics of urinary tract cancers: state of the art.

Neymark N, Torfs K.

Eur Urol. 1997;31 Suppl 1:72-81. Review.

PMID:
9076488

Supplemental Content

Loading ...
Support Center